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We describe the development of nanoscale polymer drug carriers for the combinational delivery of an anticancer 
drug (doxorubicin: DOX) along with super paramagnetic iron oxide nanoparticles (IONPs). The drug molecules 
were electrostatically loaded into both block copolymer self-assembled nanoassemblies (SNAs) and cross-linked 
nanoassemblies (CNAs). Both nanoassemblies entrapped DOX and IONPs either individually or in tandem, 
maintaining sub-100 nm diameter. The IONP-loaded nanoassemblies generated heat in the presence of an 
alternating magnetic field (AMF). Incorporation of the drug payload, DOX, showed no adverse effects on the 
heating profile. Drug release from the SNAs and CNAs was accelerated as temperature increased from the 
normal body temperature (37°C) to a mild hyperthermic condition (40  42°C). CNAs released DOX faster than 
SNAs regardless of an incubation temperature. CNAs co-entrapped IONPs and DOX were more stable than 
SNAs in aqueous solutions for five days. These results suggest that block copolymer cross-linked nanoassemblies 
provide viable delivery platforms for combination delivery of inorganic molecules, anticancer drugs, and 
potentially other various biologically active substances. 
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INTRODUCTION 
 
Polymer nanoassemblies, molecular complexes typically 
prepared from biocompatible block copolymers, are widely used in 
current cancer research as drug carriers that can circulate in the 
body for a prolonged period of time and accumulate in tumor 
tissues efficiently  (Ishida et al., 1999; Lee et al., 2010). Previous 
studies have demonstrated that spherical polymer nanoassemblies, 
20 ~ 200 nm vesicles and particles, can entrap various molecules 
for diagnosis, imaging, and treatment of cancer  (Bae et al., 2009; 
Khemtong et al., 2009; Torchilin 2011). In comparison to 
conventional anticancer therapy with small molecules (< 1,000 
Da), chemotherapy using polymer nanoassemblies as drug carriers 
can reduce non-specific drug distribution in normal tissues by 
increasing the concentration of drug payloads preferentially in 
tumors  (Matsumura et al., 1986; Maeda et al., 2000). Polymer 
nanoassemblies are also shown to overcome other pharmaceutical 
obstacles for anticancer drugs, such as poor water solubility, low 
bioavailability, and unacceptable systemic toxicity  (Bae et al., 
2009). 
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Despite these potential benefits, polymer nanoassemblies 
still need to be improved to control drug release in tumors for 
effective cancer chemotherapy because most anticancer drugs are 
designed to kill fast growing cancer cells by inhibiting signal 
pathways for cell survival during the cell division, and drug 
concentrations and timing of treatment are crucially important to 
maximize therapeutic efficacy (Kim et al., 2002; Los et al., 2003; 
Fulda et al., 2006). Although polymer nanoassemblies that release 
drug slowly in the blood are expected to reduce systemic toxicity, 
they could also release drug too slowly to maintain therapeutic drug 
concentrations in tumor tissues  (Fang et al., 2011). These facts 
suggest that polymer nanoassemblies that accelerate drug release 
selectively in tumor tissues in a controlled manner may improve 
anticancer chemotherapy while reducing systemic toxicity.  
Numerous approaches have been developed to control 
drug release from polymer nanoassemblies in response to external 
stimuli, such as pH, light, ultrasound, and heat alone or in 
combination  (Sanvicens et al., 2008; Bae et al., 2009). Heat is 
particularly useful to control drug release because the body 
temperature is precisely regulated. Various methods are currently 
available to increase temperature in specific tissues locally, using     
. 
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heating probes, plates, and inorganic nanomaterials (e.g. gold and 
iron oxide). Among these heating sources, iron oxide nanoparticles 
(IONPs) with superparamagnetic properties have drawn 
considerable attention because they can generate heat in the 
presence of an alternating magnetic field (AMF)  (Neuberger et 
al., 2005; Frimpong et al., 2008; Frimpong et al., 2010; Frimpong 
et al., 2010; Meenach et al., 2010; Meenach et al., 2010; Satarkar 
et al., 2010; He et al., 2011; Satarkar et al., 2011). IONPs can be 
also used as a T2 contrast agent for magnetic resonance 
imaging  (Bulte et al., 2004). Such dual heating and imaging 
properties enable IONPs to be used for theranostics  (Sumer et al., 
2008). However, IONPs have poor particle stability and 
agglomerate easily in aqueous solutions, causing toxicity to the 
human body  (Mahmoudi et al., 2009; Singh et al., 2010; Soenen 
et al., 2010; Mahmoudi et al., 2011; Shen et al., 2012). Particle 
stability of IONPs can be improved by surface modification or 
using solubilizer (e.g. surfactants and water soluble 
polymers)  (Laurent et al., 2008). Hydrophobic and ionic 
interactions have been identified as two major factors for block 
copolymers to self-assemble into polymer nanoassemblies, and 
regardless of the payload, particle size and stability are critically 
important for the polymer nanoassemblies to achieve successful 
tumor accumulation  (Jain et al., 2008; Lin et al., 2008), yet            
. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
critical issues, such as precipitation, agglomeration, and protein 
adsorption in vivo, are not resolved completely.  
For these reasons, previous studies have been focused 
mainly on stabilizing IONP-loaded nanoparticles, and little efforts 
have been made to co-entrap IONPs and other therapeutic agents 
into a single nanoparticle for combination delivery  (Harris et al., 
2003; Prompruk et al., 2005; Kumagai et al., 2007; Papaphilippou 
et al., 2009; Konwarh et al., 2010; Lee et al., 2011; Schladt et al., 
2011; Xie et al., 2011; Min et al., 2012). In this study, we focus on 
the development of novel nanoparticle formulations for co-
entrapment and co-delivery of IONPs and anticancer agents. We 
hypothesize that (1) stable and safe IONP-loaded nanoparticles can 
be prepared by precipitating IONPs inside polymer 
nanoassemblies, and (2) these nanoassemblies can be used to co-
entrap therapeutic agents without compromising AMF-responsive 
heating profiles of the IONPs. To test these hypotheses, we have 
prepared and characterized the self-assembled nanoassemblies 
(SNAs)  (Eckman et al., 2012) and cross-linked nanoassemblies 
(CNAs)  (Lee et al., 2011; Ponta et al., 2011; Scott et al., 2011) 
from biocompatible poly(ethylene glycol)-poly(aspartate) block 
copolymers, entrapping IONPs and an anticancer drug 
(doxorubicin: DOX), and thus potentially accelerating drug release 
in tumors in response to AMF (Figure 1).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
MATERIAL AND METHODS 
 
Fig 1. Polymer nanoassemblies used in this study to entrap IONPs and DOX in combination. Self-assembled nanoassemblies (SNAs, light blue) and cross-linked 
nanoassemblies (CNAs, dark green) were prepared from the same block copolymer [PEG-poly(aspartate)], and categorized into eight groups (1: IONP-loaded 
SNAs; 2: DOX-loaded SNAs; 3: Physical mixture of 1 and 2; 4: IONP/DOX co-entrapped SNAs; 5: IONP-loaded CNAs; 6: DOX-loaded CNAs; 7: Physical 
mixture of 5 and 6; and 8: IONP/DOX co-entrapped CNAs). 
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MATERIALS  
Triphosgene, L-aspartic acid β-benzyl ester (BLA), 
N,N’-diisopropylcarbodiimide (DIC), N-hydroxysuccinimide 
(NHS), 4-(dimethylamino)pyridine (DMAP), anhydrous 
tetrahydrofuran (THF), anhydrous hexane, diethyl ether, 
dimethylsulfoxide (DMSO), phosphate buffer solution, phosphate 
buffered saline (PBS), 1,8-diaminooctane, doxorubicin 
hydrochloride (DOX-HCl), sodium hydroxide (NaOH), iron(II) 
chloride tetrahydrate, iron(III) chloride hexahydrate, and 
ammonium hydroxide (NH4OH) were purchased from Sigma-
Aldrich (USA). α-Methoxy-ω-amino poly(ethylene glycol) (PEG, 
12 kDa) was purchased from NOF Corporation (Japan). Dialysis 
bags with molecular weight cut off (MWCO) 6  8 kDa and Slide-
A-Lyzer G2 dialysis cassettes with MWCO 10 kDa, were 
purchased from Fisher Scientific (USA). SpectraPor 6 dialysis 
tubing with MWCO 50 kDa was purchased from Spectrum Labs 
(USA).  
 
Block copolymer synthesis  
Block copolymers were synthesized as reported 
previously  (Bae et al., 2005; Lee et al., 2011). β-Benzyl-L-
aspartate N-carboxy anhydride (BLA-NCA) was prepared as a 
monomer by reacting BLA with triphosgene (1.3 molar 
equivalent) in dry THF (50  100 mg/mL) at 45 C until the 
solution turned clear. Anhydrous hexane was added to the solution 
to recrystallize BLA-NCA at -20 C. The amino group of PEG was 
used to initiate polymerization of BLA-NCA in DMSO (50 
mg/mL) at 45 C under nitrogen for 2 days. The polymerization 
produced PEG-poly(β-benzyl L-aspartate) [PEG-PBLA], followed 
by precipitation in diethyl ether and freeze drying. The block 
copolymer composition was determined by proton nuclear 
magnetic resonance (
1
H-NMR) spectra from PEG (3.5 ppm) and 
benzyl groups (7.3 ppm). The purity of block copolymers was 
determined by gel permeation chromatography (GPC, Shimadzu 
LC20), using PBS mobile phase and PEG standard. 
 
Synthesis of CNAs  
The CNAs were synthesized as previous reported with 
slight modification  (Lee et al., 2011). A two molar excess of 
NaOH was added to PEG-PBLA to remove the benzyl groups. 
Excess NaOH and other impurities were removed by dialysis. The 
solution was treated further with HCl to remove sodium salt, and 
freeze dried to collect PEG-poly(aspartate) [PEG-p(Asp)]. PEG-
p(Asp) was dissolved in DMSO to a final concentration of 50 
mg/mL. DIC, NHS, and DMAP were added to the solution at a 
molar ratio of 4:4:0.2 with respect to the number of the aspartate 
units of PEG-p(Asp). This solution was mixed with 1,8-
diaminooctane [0.5 equivalent to carboxyl groups of p(Asp)] at 45 
C for 72 hours. CNAs were dialyzed against water, and collected 
by freeze drying. 
 
Preparation and Characterization of Nanoassemblies 
Entrapping IONPs and DOX    
 Iron oxide (Fe3O4) was formed in the presence of either 
PEG-p(Asp) block copolymers or CNAs to simultaneously 
precipitate and entrap IONPs inside polymer nanoassemblies. Iron 
ions were added to PEG-p(Asp) and CNAs in a molar ratio of 1:1 
(a ratio of 2:1 of Fe
3+
:Fe
2+
) with respect to carboxylic groups on 
the polymer chains. Ammonium hydroxide was then slowly added 
to the solution to precipitate the iron oxide, producing SNAs and 
CNAs entrapping IONPs (1 and 5 in Figure 1). IONPs that were 
formed outside of the polymer nanoassemblies aggregated and 
precipitated in the solutions while the IONPs entrapped inside the 
SNAs and CNAs remained soluble in the supernatant. Free IONPs 
as well as free ions (iron and sodium) were removed from the 
solution by centrifugation and dialysis. SNAs and CNAs 
entrapping IONPs were collected by freeze drying. DOX was 
entrapped in the polymer nanoassemblies through combined ionic 
and hydrophobic interactions. DOX-HCl was mixed with PEG-
p(Asp) or CNAs in deionized water, followed by dialysis and 
ultracentrifugal filtration (30 kDa) until no free DOX was 
detected. SNAs and CNAs entrapping DOX were collected by 
freeze drying (2 and 6 in Figure 1). Polymer nanoassemblies co-
entrapping IONPs and DOX were prepared by mixing DOX-HCl 
with the polymer nanoassemblies pre-loaded with IONPs. The 
products were collected by dialysis against water and freeze drying 
(4 and 8 in Figure 1). Physical mixtures of individual 
nanoassemblies entrapping either IONPs or DOX separately were 
prepared as comparison (3 and 7 in Figure 1). IONP loading yields 
were determined by weight % (wt%), using thermogravimetric 
analysis (TGA) instruments. Fourier transform infrared 
spectroscopy (FT-IR) was used to confirm the presence of 
polymers in IONP-loaded nanoassemblies. DOX entrapment 
yields were quantified by UV-Vis absorbance measurements at 
480 nm. Particle sizes of all samples were determined by dynamic 
light scattering (DLS) measurements (Zetasizer Nano ZS, 
Malvern). Data are shown as average from triplicate measurements 
± standard deviation (SD).  
 
Heating of IONP-Loaded Polymer Nanoassemblies  
Heating capability of IONP-loaded SNAs and CNAs was 
determined in the presence of AMF, using a custom made 
induction power supply (Taylor Winfield, MMF-3-135/400-2). 
IONP-loaded nanoassemblies were dissolved in deionized water at 
2 mg/mL and placed in a 1.5 mL microtube. The solution was 
placed inside the coil of the AMF unit, using a Luxtron FOT lab 
kit temperature probe (LumaSense Technologies) to monitor the 
overall solution temperature of the sample. A baseline temperature 
was obtained from a blank solution for 30 seconds and the AMF 
was switched on at 70% power, corresponding to a field strength 
of approximately 59.3 kA/m at 300 kHz. The temperature was then 
monitored for 15 minutes. Images of the AMF-induced heating of 
the IONP-loaded nanoassemblies were captured using an infrared 
(IR) camera (SC4000, FL-IR Systems).  
IONP-loaded nanoassemblies in water (2 mg/mL) were 
placed in a 35 mm culture dish and set on top of the AMF coil 
(33.4 kA/m at 300 kHz) for taking IR images. The change in the 
heating profile based on IONP concentration was evaluated 
024                       Scott et al. / Journal of Applied Pharmaceutical Science 3 (06); 2013: 021-028  
 
through the application of AMF to varying IONP-CNA 
concentrations. The total IONP-CNA concentrations were set at 1, 
2.5, and 5 mg/mL based on IONPs, followed by the application of 
AMF. The initial temperature was held at either 25ºC or 37ºC by a 
customized warming chamber. 
 
Evaluation of Temperature Dependent Drug Release 
The influence of heat on drug release from polymer 
nanoassemblies was determined by evaluating SNAs and CNAs 
that co-entrapping IONPs and DOX. The polymer nanoassemblies 
(300 µL of 2 mg DOX/mL) were put in three dialysis cassettes 
(Slide-A-Lyzer G2, MWCO 10 kDa, Thermo Scientific, USA). 
The sample solutions were dialyzed in excess phosphate buffer 
solutions (pH 7.4, 20 mM) while the temperature was maintained 
at either 37ºC or 45ºC. An aliquot of 20 µL was taken out of each 
dialysis cassette at 0, 0.5, 1, 2, 4, and 6 hours. DOX remaining in 
the dialysis cassettes were quantified by UV/Vis absorbance at 480 
nm. All experiments were performed in triplicate.   
 
Stability of Nanoassemblies 
The stability of SNAs and CNAs co-entrapping IONPs 
and DOX was investigated over a period of 5 days. The polymer 
nanoassemblies were dissolved in deionized water at 2 mg/mL, 
and added to a disposable capillary tube. The nanoparticles were 
stored at room temperature and the particle size was observed by 
DLS in triplicate on days 1, 3, and 5. 
 
RESULTS AND DISCUSSION 
 
Synthesis of block copolymers and CNAs  
1
H-NMR analysis determined that polymerization of 
BLA-NCA produced PEG-PBLA with 28 aspartate repeating 
units. GPC was used to confirm the purity of the polymer and the 
cross-linking of PEG-p(Asp) with 1,8-diaminooctane. A single 
peak of PEG-p(Asp) on GPC shifted to a higher molecular range 
with a shorter elution time after the cross-linking reaction (Figure 
2).  
 
 
Fig 2. GPC spectra of PEG (12 kDa), PEG-p(Asp) block copolymers, and 
CNAs. 
A relatively narrow distribution of the CNAs was also 
observed with a Mw/Mn of 1.14. Neither unreacted polymers nor 
impurities were detected after purification of CNAs. The average 
molecular weight of CNAs was approximately 129 kDa, indicating 
that one CNA particle contained 7 ~ 8 block copolymer chains. 
These results were consistent with what we observed 
previously  (Lee et al., 2011; Eckman et al., 2012).  
 
Entrapment of IONPs and DOX  
IONPs are normally stabilized with citric acid or 
surfactants to avoid agglomeration  (Laurent et al., 2008). In this 
study, we used PEG-p(Asp) or CNAs as stabilizers to 
simultaneously prepare and entrap IONPs inside polymer 
nanoassemblies. This approach allowed us to control the particle 
size of polymer nanoassemblies within a clinically relevant range 
(< 100 nm). Successful incorporation of IONPs into the polymer 
nanoassemblies was achieved at a 2:1 ratio of Fe
3+
:Fe
2+
 in solution 
with an equivalent amount of carboxyl groups of PEG-p(Asp) or 
CNAs. The solution containing iron ions and polymers formed 
dark brown precipitates immediately after NH4OH was added. 
IONPs entrapped in polymer nanoassemblies were readily 
separated from free IONPs by centrifugation as the entrapped 
IONPs remained soluble in aqueous solutions. The supernatant 
was collected and dialyzed to remove unreacted iron ions and 
other impurities, followed by freeze drying.  
DOX was also successfully entrapped in either empty or IONP-
loaded nanoassemblies. DOX and PEG-p(Asp) block copolymers 
formed SNAs spontaneously as they were mixed in deionized 
water. The amount of DOX loaded into nanoassemblies was 
quantified by UV-Vis absorbance at 480 nm (25.6 wt%). FT-IR 
was used to confirm IONP incorporation into polymer 
nanoassemblies (Figure 3).  
 
 
 
Fig 3. FT-IR characterization (a: IONPs; b: IONP-loaded polymer 
nanoassemblies; c: IONP/DOX co-entrapped polymer nanoassemblies; e: ether 
peak at 1,100 cm-1; and f: amide peak at 1,650 cm-1). 
 
 
IONPs are dark brown materials, which were easily detected by 
color in our IONP-loaded polymer nanoassemblies after 
purification. The ether peak at 1,100 cm
-1
 and amide at 1,650 cm
-1
 
indicated the presence of PEG and p(Asp), respectively. These 
unique polymer peaks appeared in both IONP-loaded 
nanoassemblies and nanoassemblies co-entrapping IONP and 
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DOX while the IONPs alone lacked the peaks of interest. It is 
possible that unencapsulated IONPs and free block copolymers 
could result in a similar FTIR trace. However, unencapsulated 
IONPs precipitate easily and cannot be present in aqueous 
solutions, following several purification steps used for IONP-
loaded nanoparticles. TGA confirmed that polymer 
nanoassemblies contained 26 wt% of IONPs (Figure 4). The 
particle sizes of nanoassemblies are summarized in Table 1, 
indicating that the average diameter was less than 100 nanometers 
regardless of the nanoassembly composition.  
 
 
Fig 4. TGA characterization and the IONP loading yield in CNAs. 
Table 1.Size comparison of polymer nanoassemblies entrapping IONPs and 
DOX. 
 
Samples 
Diameter  SD 
(nm) 
IONP-loaded SNAs 34.4 ± 6.0 
DOX-loaded SNAs 57.7 ± 3.3 
IONP/DOX co-entrapped SNAs 54.3 ± 6.5 
Physical mixture of IONP- and DOX-loaded SNAs 46.0 ± 8.8 
IONP-loaded CNAs 64.0 ± 10.4 
DOX-loaded CNAs 70.6 ± 4.7 
IONP/DOX co-entrapped CNAs 75.0 ± 11.0 
Physical mixture of IONP- and DOX-loaded CNAs 67.5 ± 10.9 
 
Heating profile of IONP-loaded polymer nanoassemblies 
The heating ability of IONPs inside polymer 
nanoassemblies was investigated using a temperature probe and an 
IR camera in the presence of AMF. In Figure 5A, nanoparticle 
solutions (1 ~ 5 mg IONP/mL) reached the hyperthermic 
temperature range (40 ~ 42ºC) in 600 seconds in the presence of 
AMF. As the concentration of IONP-loaded CNAs increased, the 
observed solution temperature also increased. However, the 
temperature of solution at 1 mg IONP/mL was always lower than 
nanoassembly solutions at higher IONP concentrations (2.5 or 5 
mg/mL) and showed no further increase over time. It is noticeable 
that initial solution temperatures (37ºC vs 25ºC) did not change the 
heating rate of polymer nanoassemblies (Figure 5A and 5B). These 
results indicate that the concentration of IONPs in the solution is 
the major factor that affects heating profiles of IONP-loaded 
polymer nanoassemblies. Figure 5 B indicates that polymer 
nanoassemblies retain the heating profile in the absence (a) and 
presence (b) of drug payloads (DOX). IR images show that the 
heating efficiency of IONPs inside polymer nanoassemblies 
changed substantially inside and over the AMF coil (c and d in 
Figure 5B).  
 
 
 
 
 
Fig 5. Heating profiles of IONP-loaded CNAs. (A) The changes in solution 
temperature upon the application of AMF were observed at different particle 
concentrations (control: deionized water). (B) Effects of drug payloads on the 
heating profile were also investigated (a: IONP-loaded CNAs alone; b: 
IONP/DOX co-entrapped CNAs; c: infrared thermal image of a blank; and d: 
thermal images of IONP-loaded CNAs. AMF generating coils are shown in 
white circles.) 
 
These results demonstrate the ability to tune the heat 
produced by the IONP-loaded nanoassemblies and allow 
adjustments in order to minimize heat damage to other normal 
tissue outside of the accumulated area while maximizing the 
effectiveness of the treatment. In addition, these remotely heatable 
nanoassemblies can carry drug payloads at the same time without 
compromising the heating profiles, allowing unique hyperthermia 
and chemotherapy combination. We envision that, by selectively 
applying an AMF to the area of interest after the nanoparticles 
have accumulated in the tumor, heat and the accelerated drug 
release can be confined to the tumor and aid in reducing non-
specific side effects. Remote heating of IONP-loaded polymer 
nanoassemblies is useful not only for drug release acceleration but  
also for heat-induced therapies such as hyperthermia or 
thermoablation (Meenach et al., 2010). The range of temperature 
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that these polymer nanoassemblies can modulate is still dependent 
largely on the concentration of the nanoassemblies and power of 
AMF. We observed a significant decrease in heating efficiency 
between polymer nanoassemblies in and over the AMF coil. The 
optimal design of AMF-generating devices might improve the 
heating of polymer nanoassemblies in vivo, allowing focused 
heating for drug release acceleration and therapy. Recent work has 
demonstrated IONPs possess a therapeutic effect outside of the 
heating of the cancer cells. Magnetic nanoparticles were shown to 
reduce cell viability to 2  5% when exposed to an alternating 
magnetic field even without raising the solution 
temperature  (Wust et al., 2002; Marcos-Campos et al., 2011). 
Therefore, IONP/DOX loaded polymer nanoassemblies may 
exhibit a beneficial therapeutic effect as AMF-responsive 
nanomaterials in vivo, although potential effects of AMF and 
magnetic fields in vivo (e.g. heating of tissue for 10 minutes as 
tested in this study) are not fully understood yet  (Lednev 1991; 
Walleczek 1992; Grissom 1995). 
 
Temperature-dependent drug release  
Drug release patterns from polymer nanoassemblies co-
entrapping IONPs and DOX were determined at 37ºC and 45ºC 
(pH 7.4, 20 mM PBS), corresponding to the physiological and 
hyperthermic condition, respectively. Both SNAs and CNAs 
accelerated drug release as the temperature increased from 37ºC to 
45ºC, although the difference was subtle (Figure 6).  
 
 
Fig 6. The influence of temperature on drug release patterns from SNAs (A) 
and CNAs (B). All data points are the average of three measurements ± 
standard deviation. 
 
Such accelerated drug release gradually slowed down 
after 2 hours, following pseudo-zero order drug release in the early 
stage. These bi-modal drug release patterns are expected to fine-
tune optimal drug concentrations in tumors in future in vivo 
applications. Although an increased temperature (e.g. 45ºC as 
tested in this study) could damage normal tissues, pinpoint 
hyperthermia using our IONP-loaded CNAs would reduce such 
potential risks. In addition, AMF can switch on and off the heating 
and accelerating drug release in a remotely controlled manner, 
which will further reduce potential toxicity by hyperthermia with 
IONP-loaded nanoassemblies.  
Interestingly, there was no significant difference between 
SNAs and CNAs in the drug release profile. These results imply 
that polymer nanoassemblies entrapping IONPs may have a 
similar core environment, where IONPs occupy the center of core 
and DOX gets weakly bound to the core. It is also possible that 
drug molecules were indeed entrapped inside the nanoassembly 
core, yet failed to come out as more than 20% of drugs still 
remained in the nanoassemblies. Therefore, accelerated drug 
release is likely attributed to temperature-dependent changes in 
hydration of PEG of the particles, affecting mainly the drugs along 
the boundary region between the core and shell. Hydration is one 
of the factors that influence molecular diffusion in a layer and 
matrix made of PEG. PEG is a flexible polymer chain, but SNAs 
and CNAs tether PEG chains to an IONP-loaded core, providing a 
nanoscale PEG compartment in the shell, a physical barrier that 
drug molecules need to go through. Therefore, IONPs generating 
heat in the presence of AMF may enhance molecular diffusion of 
DOX from the polymer nanoassemblies, although we were unable 
to direct observe such a phenomenon due to the technical issue to 
apply AMF to nanoparticles inside dialysis cassettes in a large 
water bath (> 5 L).  
 
Stability of Polymer Nanoassemblies  
The stability of polymer nanoassemblies co-entrapping 
IONPs and DOX (co-entrapped type) was evaluated in deionized 
water over five days, while preparing a mixed solution of 
nanoassemblies entrapping IONPs or DOX separately (physically 
mixed type) as a control. In Figure 7A, the particle size of 
physically mixed SNAs decreased time-dependently, and the 
observed particle size decreased by 63% over a period of 5 days (a, 
b, and c). Co-entrapped type SNAs retained their particle size for 5 
days (d, e, and f in Figure 7A). However, both physically mixed 
and co-entrapped SNAs generated precipitates in solutions. The 
particle sizes of CNAs remained unchanged in physically mixed 
and co-entrapped types (Figure 7B).  
 
 
 
Fig 7. Time-dependent changes in particle sizes of SNAs (A) and CNAs (B) 
entrapping IONPs and DOX (a: Physically mixed type on day 1; b: Physically 
mixed type on day 3; c: Physically mixed type on day 5; d: Co-entrapped type 
on day 1; e: Co-entrapped type on day 3; and f: Co-entrapped type on day 5). 
All points are shown the average of three measurements ± standard deviation. 
(*: P < 0.05). 
 
No precipitates were observed in CNAs, suggesting that 
IONPs and DOX were entrapped effectively in polymer 
nanoassemblies due to the cross-linked core. Interestingly the 
polymer nanoassemblies co-entrapping IONPs and DOX (both 
SNAs and CNAs) showed improved stability with no significant 
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change in the observed size. One possible reason is that IONPs 
could act as a cross-linker and hold multiple block copolymers 
together to prevent dissociation. In a physically mixed 
formulation, CNAs showed greater particle stability than SNAs. 
CNAs with enhanced particle stability can be also used to 
introduce other functional groups without compromising the 
particle stability. In fact, particle stability is an emerging issue for 
nanoparticulate drug carriers as numerous approaches have been 
used to control drug release by introducing functional groups that 
are sensitive to heat, light, and pH  (Bae et al., 2009). Previous 
studies employed a method through which pre-formed iron oxide 
particles were entrapped in the polymer matrice, particles, or 
complexes  (Kumagai et al., 2007; Sanvicens et al., 2008; Obena 
et al., 2011). On the contrary, we prepared cross-linked 
nanoassemblies first, reacted the nanoassemblies with iron ions, 
and prepared IONP-loaded nanoassemblies in a single pot. This 
method, co-precipitating Fe3O4 iron oxides inside the 
nanoassemblies directly, was confirmed efficient and convenient 
to prepare IONP-loaded nanoparticles with homogeneous particle 
sizes and enhanced particle stability. 
 
CONCLUSION 
 
Block copolymer self-assembled and cross-linked 
nanoassemblies (SNAs and CNAs) were prepared in this study to 
develop novel nanoscale carriers for the delivery of iron oxide 
nanoparticles (IONPs) and anticancer drug (DOX) in combination 
to disease sites in the body (e.g. tumors). Polymer nanoassemblies 
entrapping IONPs and DOX were successfully prepared by 
precipitating iron oxide inside the polymer nanoassemblies, and 
the particle sizes were < 100 nm, which is clinically relevant for 
macromolecules to accumulate in tumor tissues. IONP-loaded 
SNAs and CNAs generated heat in the presence of an alternating 
magnetic field (AMF), and the concentrations of IONPs in a 
solution played a major role in controlling the temperature. 
Heating properties of IONP-loaded nanoparticles were retained 
even after entrapping DOX in the SNAs and CNAs. Drug release 
from the polymer nanoassemblies was accelerated as temperature 
increased, yet the change was subtle presumably because IONPs 
occupy the core of nanoassemblies while drug molecules were 
weakly bound to the core or entrapped in the shell. Despite similar 
drug release patterns, CNAs showed greater particle stability than 
SNAs during storage in solutions, suggesting that CNAs would be 
a suitable candidate to further develop IONP/DOX co-entrapped 
polymer nanoassemblies for future applications, such as AMF-
mediated remote heating and triggered drug release in vivo.  
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